DAX23.335 +1,1%ESt505.283 ±-0,0%Top 10 Crypto11,95 -4,0%Dow41.405 +0,2%Nas17.886 -0,5%Bitcoin82.845 -0,6%Euro1,1313 +0,1%Öl59,78 -2,7%Gold3.312 +2,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 NVIDIA 918422 BASF BASF11 RENK RENK73 Berkshire Hathaway A0YJQ2 Novo Nordisk A3EU6F Lufthansa 823212 Allianz 840400 Siemens Energy ENER6Y Mercedes-Benz Group (ex Daimler) 710000 Tesla A1CX3T BP 850517 HENSOLDT HAG000 Deutsche Bank 514000 Amazon 906866
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX beendet Handel im Plus -- Berkshire mit Gewinnrückgang - Buffett will aufhören -- BYD steigert Absatz im April -- Shell, BP, D-Wave, BioNTech, NVIDIA, Rheinmetall, SAP im Fokus
Top News
DAX schließt nach Freitags-Rally über 23.300-Punkte-Marke - Zollpolitik bleibt im Fokus DAX schließt nach Freitags-Rally über 23.300-Punkte-Marke - Zollpolitik bleibt im Fokus
Novo Nordisk-Aktie im Aufwind: Novo Nordisk triumphiert mit Wegovy in den USA Novo Nordisk-Aktie im Aufwind: Novo Nordisk triumphiert mit Wegovy in den USA
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Nicht an der Qualität sparen: Mit Anlagelösungen der Landesbank Baden-Württemberg. Jetzt mehr erfahren

Regeneron Pharmaceuticals Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
533,00 EUR -5,00 EUR -0,93 %
STU
606,09 USD -0,03 USD -0,01 %
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.57,72 Mrd. EUR

KGV18,58Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN881535

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS75886F1075

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolREGN

Regeneron Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireMedison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo® (cemiplimab) in Multiple Countries
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN
PR NewswireHigh School Scientists and Engineers Win Nearly $9 Million at the Regeneron International Science and Engineering Fair 2023
PR NewswireStudents Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease
PR NewswireTop 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition
PR NewswireLibtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer
PR NewswirePositive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine
PR NewswireRegeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
PR NewswireDupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Eosinophilic Esophagitis
PR NewswireDupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis
PR NewswireOdronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial
PR NewswireLinvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma
PR NewswireRegeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year
PR NewswirePivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH
PR NewswireRegeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo® (cemiplimab) in Multiple Solid Tumor Types
PR NewswireEvkeeza® (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review
RSSForm 4 872589
PR NewswireLibtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology
PR NewswireRegeneron and CytomX Announce Strategic Research Collaboration in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer
PR NewswireDupixent® (dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis
RSSForm 4 872589
PR NewswireLibtayo® (cemiplimab-rwlc) in Combination with Chemotherapy Approved by the FDA as First-line Treatment for Advanced Non-small Cell Lung Cancer (NSCLC)
PR NewswireAflibercept 8 mg Late-breaking Data Presented at Retina Society in Diabetic Macular Edema and Wet Age-related Macular Degeneration
PR NewswireRegeneron Announces Investor Conference Presentations
PR NewswireRegeneron Presents New Data at ASH from Advancing Hematology Pipeline across Multiple Blood Cancers and Disorders
PR NewswireRegeneron Reports Third Quarter 2022 Financial and Operating Results
RSSForm 10-Q 872589
RSSForm 8-K 872589
RSSForm 4 872589
PR NewswireInmazeb™ (atoltivimab, maftivimab, and odesivimab-ebgn) Wins Prestigious 2022 Prix Galien USA Best Biotechnology Product Award
PR NewswireRegeneron Receives Six Months of U.S. Pediatric Exclusivity for EYLEA® (aflibercept) Injection
PR NewswireLibtayo® (cemiplimab) Receives Positive CHMP Opinion Recommending Approval to Treat Advanced Cervical Cancer
PR NewswireEYLEA® (aflibercept) Injection sBLA for Treatment of Retinopathy of Prematurity (ROP) Accepted for FDA Priority Review
PR NewswireDupixent® (dupilumab) Late-Breaking Phase 3 Data Presented at UEG Week 2022 Showed Significant Histological Remission of Eosinophilic Esophagitis (EoE) in Children 1 to 11 Years Old
PR NewswireRegeneron to Report Third Quarter 2022 Financial and Operating Results and Host Conference Call and Webcast on November 3, 2022
PR NewswireRegeneron Elects Dr. Craig B. Thompson to Board of Directors
PR NewswireAflibercept 8 mg Positive Pivotal Results in Diabetic Macular Edema and Wet Age-Related Macular Degeneration Presented at AAO
PR NewswireDupixent® (dupilumab) Approved by FDA as the First and Only Treatment Indicated for Prurigo Nodularis
PR NewswireIntellia and Regeneron Announce Initial Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis
PR NewswireRegeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
Wer­bung

Regeneron Pharmaceuticals News

Regeneron Pharmaceuticals News: auf dieser Seite finden Sie alle Regeneron Pharmaceuticals News und Nachrichten zur Regeneron Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Regeneron Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Regeneron Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.